Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension
Jacques P. Brown(Centre hospitalier de l'Université Laval), Ian R. Reid(University of Auckland), Ivo Valter(Vähiuuringute Tehnoloogia Arenduskeskus), Paul D. Miller(University of North Carolina at Chapel Hill), David W. Dempster(Columbia University), Michael A. Bolognese, Nadia Daizadeh, Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), David L. Kendler(University of British Columbia), Rachel B. Wagman(Amgen (United States)), José Zanchetta(Universidad del Salvador)
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k